Crystal Structures of Clinically Relevant Lys103Asn/Tyr181Cys Double Mutant HIV-1 Reverse Transcriptase in Complexes with ATP and Non-nucleoside Inhibitor HBY 097

This publication has 59 references indexed in Scilit:

• Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases
  Current Opinion in Structural Biology, 2004
• Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV-1–Infected Patients With Failure of Highly Active Antiretroviral Therapy
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Resistance against Reverse Transcriptase Inhibitors
  Clinical Infectious Diseases, 2000
• Factors associated with the successful modification of antiretroviral therapy
  AIDS, 2000
• Update on highly active antiretroviral therapy: progress and strategies
  Biomedicine & Pharmacotherapy, 2000
• Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
  AIDS, 2000
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
  Il Farmaco, 1999
• In search of a selective antiviral chemotherapy
  Clinical Microbiology Reviews, 1997
• Insights Into HIV Chemotherapy*
  AIDS Research and Human Retroviruses, 1992